Anti-interleukin-2 receptor antibodies—basiliximab and daclizumab—for the prevention of acute rejection in renal transplantation

References

• HariharanSJohnsonCPBresnahanBATarantoSEMcIntoshMJStableinDImproved graft survival after renal transplantation in the United States, 1988 to 1996N Engl J Med2000342960561210699159
   PubMed Web of Science ®Google Scholar
• MatasAJGillinghamKJPayneWDNajarianJSThe impact of an acute rejection episode on long-term renal allograft survival (t1/2)Transplantation19945768578598154032
   PubMed Web of Science ®Google Scholar
• AlmondPSMatasAGillinghamKRisk factors for chronic rejection in renal allograft recipientsTransplantation1993554752756 discussion 756–7578475548
   PubMed Web of Science ®Google Scholar
• NankivellBJBorrowsRJFungCLO’ConnellPJChapmanJRAllenRDCalcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histologyTransplantation200478455756515446315
   PubMed Web of Science ®Google Scholar
• CitterioFSteroid side effects and their impact on transplantation outcomeTransplantation20017212 SupplS75S8011833145
   PubMed Web of Science ®Google Scholar
• JamilBNichollsKBeckerGJWalkerRGImpact of acute rejection therapy on infections and malignancies in renal transplant recipientsTransplantation199968101597160310589961
   PubMed Web of Science ®Google Scholar
• KirkmanRLShapiroMECarpenterCBA randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantationTransplantation19915111071131846250
   PubMed Web of Science ®Google Scholar
• ReedMHShapiroMEStromTBProlongation of primate renal allograft survival by anti-Tac, an anti-human IL-2 receptor monoclonal antibodyTransplantation198947155592643232
   PubMed Web of Science ®Google Scholar
• TigheHFriendPJCollierSJDelayed allograft rejection in primates treated with anti-IL-2 receptor monoclonal antibody Campath-6Transplantation19884512262283122385
   PubMed Web of Science ®Google Scholar
• van GelderTZietseRMulderAHA double-blind, placebo-controlled study of monoclonal anti-interleukin-2 receptor antibody (BT563) administration to prevent acute rejection after kidney transplantationTransplantation19956032482527645037
   PubMed Web of Science ®Google Scholar
• NashanBMooreRAmlotPSchmidtAGAbeywickramaKSoulillouJPRandomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study GroupLancet19973509086119311989652559
   PubMed Web of Science ®Google Scholar
• KahanBDRajagopalanPRHallMReduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal anti-body. United States Simulect Renal Study GroupTransplantation199967227628410075594
   PubMed Web of Science ®Google Scholar
• KovarikJWolfPCisterneJMDisposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allograftsTransplantation19976412170117059422405
   PubMed Web of Science ®Google Scholar
• KovarikJMKahanBDRajagopalanPRPopulation pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The US Simulect Renal Transplant Study GroupTransplantation19996891288129410573065
   PubMed Web of Science ®Google Scholar
• KovarikJMOffnerGBroyerMA rational dosing algorithm for basiliximab (Simulect) in pediatric renal transplantation based on pharmacokinetic-dynamic evaluationsTransplantation200274796697112394838
   PubMed Web of Science ®Google Scholar
• VincentiFKirkmanRLightSInterleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study GroupN Engl J Med199833831611659428817
   PubMed Web of Science ®Google Scholar
• NashanBLightSHardieIRLinAJohnsonJRReduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study GroupTransplantation19996711101159921806
   PubMed Web of Science ®Google Scholar
• AhsanNHolmanMJJarowenkoMVRazzaqueMSYangHCLimited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantationAm J Transplant20022656857312118902
   PubMed Web of Science ®Google Scholar
• ter MeulenCGBaanCCHeneRJHilbrandsLBHoitsmaAJTwo doses of daclizumab are sufficient for prolonged interleukin-2Ralpha chain blockadeTransplantation200172101709171011726840
   PubMed Web of Science ®Google Scholar
• VincentiFPaceDBirnbaumJLantzMPharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantationAm J Transplant200331505212492710
   PubMed Web of Science ®Google Scholar
• ter MeulenCGvan RiemsdijkIHeneRJSteroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor alpha therapy: a prospective, randomized, multicenter studyAm J Transplant20044580381015084178
   PubMed Web of Science ®Google Scholar
• VincentiFLantzMBirnbaumJA phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantationTransplantation199763133389000657
   PubMed Web of Science ®Google Scholar
• Summary of product characteristics for Zenapax (dacliximab). 1997: Report no. RO 24-7375.
   Google Scholar
• StrehlauJPapeLOffnerGNashanBEhrichJHInterleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipientsLancet200035692381327132811073027
   PubMed Web of Science ®Google Scholar
• SifontisNMBenedettiEVasquezEMClinically significant drug interaction between basiliximab and tacrolimus in renal transplant recipientsTransplant Proc20023451730173212176554
   PubMed Web of Science ®Google Scholar
• KovarikJMPescovitzMDSollingerHWDifferential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patientsClin Transplant200115212313011264639
   PubMed Web of Science ®Google Scholar
• AmlotPLRawlingsEFernandoONProlonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantationTransplantation19956077487567570988
   PubMed Web of Science ®Google Scholar
• ThistlethwaiteJRJrNashanBHallMChodoffLLinTHReduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. The Global Simulect Study GroupTransplantation200070578479011003358
   PubMed Web of Science ®Google Scholar
• PonticelliCYussimACambiVA randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipientsTransplantation20017271261126711602853
   PubMed Web of Science ®Google Scholar
• EkbergHBackmanLTufvesonGTydenGNashanBVincentiFDaclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysisTranspl Int200013215115910836653
   PubMed Web of Science ®Google Scholar
• BumgardnerGLHardieIJohnsonRWResults of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantationTransplantation200172583984511571447
   PubMed Web of Science ®Google Scholar
• AduDCockwellPIvesNJShawJWheatleyKInterleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trialsBMJ2003326739378912689974
   PubMed Web of Science ®Google Scholar
• IversonAJVickSCSarnackiCTWrightFHJrDaclizumab in live donor renal transplantationTransplant Proc200032479079210856587
   PubMed Web of Science ®Google Scholar
• VincentiFMonacoAGrinyoJRapid steroid withdrawal versus standard steroid therapy in patients treated with basiliximab, cyclosporine, and mycophenolate mofetil for the prevention of acute rejection in renal transplantationTransplant Proc2001331–21011101211267168
   PubMed Web of Science ®Google Scholar
• CiancioGMillerABurkeGWDaclizumab induction for primary kidney transplant recipients using tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppressionTransplant Proc2001331–21013101411267169
   PubMed Web of Science ®Google Scholar
• ChowdhurySKodeRKRangannaKInduction strategy using basiliximab combined with mycophenolate MMF and immediate low-dose cyclosporin is steroid sparing and more effective than OKT3Transplant Proc2001331–21057105811267189
   PubMed Web of Science ®Google Scholar
• ChangGJMahantyHDVincentiFA calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft functionClin Transplant200014655055411127307
   PubMed Web of Science ®Google Scholar
• PisaniFBuonomonthOIariaGPreliminary results of a prospective randomized study of basiliximab in kidney transplantationTransplant Proc2001331–22032203311267613
   PubMed Web of Science ®Google Scholar
• VincentiFDaclizumab: novel biologic immunoprophylaxis for prevention of acute rejection in renal transplantationTransplant Proc19993162206220710500546
   PubMed Web of Science ®Google Scholar
• LawenJGDaviesEAMouradGRandomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantationTransplantation2003751374312544868
   PubMed Web of Science ®Google Scholar
• WebsterACPlayfordEGHigginsGChapmanJRCraigJCInterleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trialsTransplantation200477216617614742976
   PubMed Web of Science ®Google Scholar
• CiancioGBurkeGWSuzartKThe use of daclizumab, tacrolimus and mycophenolate mofetil in African-American and Hispanic first renal transplant recipientsAm J Transplant2003381010101612859538
   PubMed Web of Science ®Google Scholar
• CiancioGBurkeGWSuzartKEffect of daclizumab, tacrolimus and mycophenolate mofetil in racial minority first renal transplant recipientsTransplant Proc20023451617161812176508
   PubMed Web of Science ®Google Scholar
• Meier-KriescheHUKazaHPalekarSSThe effect of daclizumab in a high-risk renal transplant populationClin Transplant200014550951311048998
   PubMed Web of Science ®Google Scholar
• Meier-KriescheHUPalenkarSSFriedmanGSMulgaonkarSPGoldblatMVKaplanBEfficacy of Daclizumab in an African-American and Hispanic renal transplant populationTranspl Int200013214214510836651
   PubMed Web of Science ®Google Scholar
• CiancioGMattiazziARothDKupinWMillerJBurkeGWThe use of daclizumab as induction therapy in combination with tacrolimus and mycophenolate mofetil in recipients with previous transplantsClin Transplant200317542843214703925
   PubMed Web of Science ®Google Scholar
• VincentiFRamosEBrattstromCMulticenter trial exploring calcineurin inhibitors avoidance in renal transplantationTransplantation20017191282128711397963
   PubMed Web of Science ®Google Scholar
• TranHTAcharyaMKMcKayDBAvoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroidsJ Am Soc Nephrol200011101903190911004222
   PubMed Web of Science ®Google Scholar
• EkbergHGrinyoJNashanBCyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR StudyAm J Transplant20077356057017229079
   PubMed Web of Science ®Google Scholar
• FlechnerSMKurianSMSolezKDe novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two yearsAm J Transplant20044111776178515476476
   PubMed Web of Science ®Google Scholar
• FlechnerSMGoldfarbDSolezKKidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugsTransplantation200783788389217460558
   PubMed Web of Science ®Google Scholar
• Martinez-MierGMendez-LopezMTBudar-FernandezLFLiving related kidney transplantation without calcineurin inhibitors: initial experience in a Mexican centerTransplantation200682111533153617164728
   PubMed Web of Science ®Google Scholar
• EkbergHTedesco-SilvaHDemirbasAReduced exposure to calcineurin inhibitors in renal transplantationN Engl J Med2007357252562257518094377
   PubMed Web of Science ®Google Scholar
• NashanBCurtisJPonticelliCMouradGJaffeJHaasTEverolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label studyTransplantation20047891332134015548972
   PubMed Web of Science ®Google Scholar
• VitkoSTedescoHErisJEverolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studiesAm J Transplant20044462663515023156
   PubMed Web of Science ®Google Scholar
• Tedesco-SilvaHJrVitkoSPascualJ12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipientsTranspl Int2007201273617181650
   PubMed Web of Science ®Google Scholar
• HongJCKahanBDA calcineurin antagonist-free induction strategy for immunosuppression in cadaveric kidney transplant recipients at risk for delayed graft functionTransplantation20017191320132811397971
   PubMed Web of Science ®Google Scholar
• McTaggartRAGottliebDBrooksJSirolimus prolongs recovery from delayed graft function after cadaveric renal transplantationAm J Transplant20033441642312694063
   PubMed Web of Science ®Google Scholar
• BoletisJNTheodoropoulouHHirasTMonoclonal antibody basiliximab with low cyclosporine dose as initial immunosuppressionTransplant Proc2001337–83184318611750366
   PubMed Web of Science ®Google Scholar
• ParrottNRHammadAQWatsonCJLodgeJPAndrewsCDMulticenter, randomized study of the effectiveness of basiliximab in avoiding addition of steroids to cyclosporine a monotherapy in renal transplant recipientsTransplantation200579334434815699766
   PubMed Web of Science ®Google Scholar
• KamarNGarrigueVKarrasAImpact of early or delayed cyclosporine on delayed graft function in renal transplant recipients: a randomized, multicenter studyAm J Transplant200665 Pt 11042104816611342
   PubMed Web of Science ®Google Scholar
• MouradGKarrasAKamarNRenal function with delayed or immediate cyclosporine microemulsion in combination with enteric-coated mycophenolate sodium and steroids: results of follow up to 30 months post-transplantClin Transplant200721329530017488375
   PubMed Web of Science ®Google Scholar
• AndrésAMarcénRValdésFNI2A Study GroupA randomized trial of basiliximab with three different patterns of cyclosporin A initiation in renal transplant from expanded criteria donors and at high risk of delayed graft functionClin Transplant20092312332
   Web of Science ®Google Scholar
• SinclairNRLow-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study GroupCMAJ199214756456571521210
   PubMed Web of Science ®Google Scholar
• AhsanNHricikDMatasAPrednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil – a prospective randomized study. Steroid Withdrawal Study GroupTransplantation199968121865187410628766
   PubMed Web of Science ®Google Scholar
• VanrenterghemYLebranchuYHeneROppenheimerFEkbergHDouble-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejectionTransplantation20007091352135911087152
   PubMed Web of Science ®Google Scholar
• PascualJQueredaCZamoraJHernandezDSteroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of randomized, controlled trialsTransplantation200478101548155615599321
   PubMed Web of Science ®Google Scholar
• ColeELandsbergDRussellDA pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipientsTransplantation200172584585011571448
   PubMed Web of Science ®Google Scholar
• VincentiFMonacoAGrinyoJKinkhabwalaMRozaAMulticenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetilAm J Transplant20033330631112614286
   PubMed Web of Science ®Google Scholar
• RostaingLCantarovichDMouradGCorticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantationTransplantation200579780781415818323
   PubMed Web of Science ®Google Scholar
• VitkoSKlingerMSalmelaKTwo corticosteroid-free regimens-tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation: results of the Atlas studyTransplantation200580121734174116378069
   PubMed Web of Science ®Google Scholar
• WoodleESFirstMRPirschJShihabFGaberAOVan VeldhuisenPA prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapyAnn Surg2008248456457718936569
   PubMed Web of Science ®Google Scholar
• VincentiFSchenaFPParaskevasSHauserIAWalkerRGGrinyoJA randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipientsAm J Transplant20088230731618211506
   PubMed Web of Science ®Google Scholar
• PascualJZamoraJGaleanoCRoyuelaAQueredaCSteroid avoidance or withdrawal for kidney transplant recipientsCochrane Database Syst Rev20091CD00563219160257
   PubMed Web of Science ®Google Scholar
• WoodleESVincentiFLorberMIA multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimusAm J transplant20055115716615636625
   PubMed Web of Science ®Google Scholar
• Anil KumarMSHeifetsMFyfeBComparison of steroid avoidance in tacrolimus/mycophenolate mofetil and tacrolimus/sirolimus combination in kidney transplantation monitored by surveillance biopsyTransplantation200580680781416210969
   PubMed Web of Science ®Google Scholar
• KumarMSHeifetsMMoritzMJSafety and efficacy of steroid withdrawal two days after kidney transplantation: analysis of results at three yearsTransplantation200681683283916570004
   PubMed Web of Science ®Google Scholar
• GallonLPericoNDimitrovBDLong-term renal allograft function on a tacrolimus-based, pred-free maintenance immunosuppression comparing sirolimus vs MMFAm J Transplant2006671617162316827862
   PubMed Web of Science ®Google Scholar
• MontagninoGSandriniSIorioBA randomized exploratory trial of steroid avoidance in renal transplant patients treated with everolimus and low-dose cyclosporineNephrol Dial Transplant200823270771417890244
   PubMed Web of Science ®Google Scholar
• AllowayRRHanawayMJTrofeJA prospective, pilot study of early corticosteroid cessation in high-immunologic-risk patients: the Cincinnati experienceTransplant Proc200537280280315848537
   PubMed Web of Science ®Google Scholar
• Anil KumarMSMoritzMJSaaedMIAvoidance of chronic steroid therapy in african american kidney transplant recipients monitored by surveillance biopsy: 1-year resultsAm J Transplant2005581976198515996248
   PubMed Web of Science ®Google Scholar
• Anil KumarMSKhanSRangannaKMalatGSustento-ReodicaNMeyersWCLong-term outcome of early steroid withdrawal after kidney transplantation in African American recipients monitored by surveillance biopsyAm J Transplant20088357458518294153
   PubMed Web of Science ®Google Scholar
• NairMPNampooryMRJohnyKVInduction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipientsTransplant Proc20013352767276911498153
   PubMed Web of Science ®Google Scholar
• LinMMingAZhaoMTwo-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical studyClin Transplant200620332532916824149
   PubMed Web of Science ®Google Scholar
• SolteroLCarbajalHSarkissianNA truncated-dose regimen of daclizumab for prevention of acute rejection in kidney transplant recipients: a single-center experienceTransplantation200478101560156315599323
   PubMed Web of Science ®Google Scholar
• StrattaRJAllowayRRLoAHodgeEEOne-year outcomes in simultaneous kidney-pancreas transplant recipients receiving an alternative dosing regimen of daclizumabTransplant Proc20043641080108115194375
   PubMed Web of Science ®Google Scholar
• CiancioGBurkeGWSuzartKDaclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipientsTransplantation20027371100110611965039
   PubMed Web of Science ®Google Scholar
• CiancioGBurkeGWSuzartKEfficacy and safety of daclizumab induction for primary kidney transplant recipients in combination with tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppressionTransplant Proc200335287387412644172
   PubMed Web of Science ®Google Scholar
• KodeRFaKChowdhurySBasiliximab plus low-dose cyclosporin vs OKT3 for induction immunosuppression following renal transplantationClin Transplant200317436937612868995
   PubMed Web of Science ®Google Scholar
• SollingerHKaplanBPescovitzMDBasiliximab versus antithymocyte globulin for prevention of acute renal allograft rejectionTransplantation200172121915191911773888
   PubMed Web of Science ®Google Scholar
• LebranchuYBridouxFBuchlerMImmunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapyAm J Transplant200221485612095056
   PubMed Web of Science ®Google Scholar
• Abou-JaoudeMMGhantousIAlmawiWYComparison of daclizumab, an interleukin 2 receptor antibody, to anti-thymocyte globulin-Fresenius induction therapy in kidney transplantationMol Immunol20033917–181083108812835081
   PubMed Web of Science ®Google Scholar
• KyllonenLEEklundBHPesonenEJSalmelaKTSingle bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression: efficacy and safetyTransplantation2007841758217627241
   PubMed Web of Science ®Google Scholar
• MouradGRostaingLLegendreCGarrigueVThervetEDurandDSequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroidsTransplantation200478458459015446319
   PubMed Web of Science ®Google Scholar
• BrennanDCDallerJALakeKDCibrikDDel CastilloDRabbit antithymocyte globulin versus basiliximab in renal transplantationN Engl J Med2006355191967197717093248
   PubMed Web of Science ®Google Scholar
• BrennanDCSchnitzlerMALong-term results of rabbit antithymocyte globulin and basiliximab inductionN Engl J Med2008359161736173818923181
   PubMed Web of Science ®Google Scholar
• KaufmanDBLeventhalJRAxelrodDGallonLGParkerMAStuartFPAlemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction – long-term resultsAm J Transplant20055102539254816162205
   PubMed Web of Science ®Google Scholar
• CiancioGBurkeGWGaynorJJA randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immunemonitoringTransplantation200580445746516123718
   PubMed Web of Science ®Google Scholar
• CiancioGBurkeGWGaynorJJA randomized trial of thymoglobulin vs alemtuzumab (with lower dose maintenance immunosuppression) vs daclizumab in renal transplantation at 24 months of follow-upClin Transplant200822220021018339140
   PubMed Web of Science ®Google Scholar
• VincentiFLarsenCDurrbachACostimulation blockade with belatacept in renal transplantationN Engl J Med2005353877078116120857
   PubMed Web of Science ®Google Scholar
• CiancioGBurkeGWGaynorJJRandomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-upTransplantation2008861677418622280
   PubMed Web of Science ®Google Scholar
• United States Renal Data System 2007Annual Data Report – TransplantationAm J Kidney Dis2008511S155S172
   Google Scholar